Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study

Background: Pembrolizumab combined with neoadjuvant chemotherapy is the standard of care for stage II-III triple-negative breast cancer (TNBC) based on the KEYNOTE-522 trial. However, 13 % of patients experienced immune-related adverse events (irAEs) of grade ≥3 in the trial. This study aims to desc...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Matheus de Oliveira Andrade, Isabella Gonçalves Gutierres, Monique Celeste Tavares, Isadora Martins de Sousa, Flávia Cavalcanti Balint, Ana Carolina Marin Comini, Mariana Carvalho Gouveia, José Bines, Fernanda Madasi, Rafael Dal Ponte Ferreira, Daniela Dornelles Rosa, Candice Lima Santos, Daniele Assad-Suzuki, Zenaide Silva de Souza, Júlio Antônio Pereira de Araújo, Débora de Melo Gagliato, Carlos Henrique dos Anjos, Bruna M. Zucchetti, Anezka Ferrari, Mayana Lopes de Brito, Renata Cangussu, Maria Marcela Fernandes Monteiro, Paulo M. Hoff, Maria Del Pilar Estevez-Diz, Laura Testa, Romualdo Barroso-Sousa, Renata Colombo Bonadio
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-10-01
Edice:	Breast
Témata:	Triple-negative breast cancer Immunotherapy Immune-related adverse events
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S0960977625004904
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!